Pharsight

Drugs facing NCE-1 in 2031

1. Vivjoa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8236962 MYCOVIA PHARMS Metalloenzyme inhibitor compounds
Apr, 2031

(7 years from now)

US10414751 MYCOVIA PHARMS Antifungal compounds and processes for making
Mar, 2036

(11 years from now)

US9840492 MYCOVIA PHARMS Antifungal compounds and processes for making
Mar, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8754227 MYCOVIA PHARMS Metalloenzyme inhibitor compounds
Apr, 2031

(7 years from now)

US11247981 MYCOVIA PHARMS Metalloenzyme inhibitor compounds
May, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 26, 2027
Generating Antibiotic Incentives Now (GAIN) Apr 26, 2032

Drugs and Companies using OTESECONAZOLE ingredient

NCE-1 date: 2031-04-27

Market Authorisation Date: 26 April, 2022

Treatment: Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of reproductive potential

Dosage: CAPSULE;ORAL

More Information on Dosage

VIVJOA family patents

Family Patents

2. Voquezna Dual Pak patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7977488 PHATHOM 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186411 PHATHOM Pharmaceutical composition
Aug, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 3, 2027
Generating Antibiotic Incentives Now (GAIN) May 3, 2032

Drugs and Companies using AMOXICILLIN; VONOPRAZAN FUMARATE ingredient

NCE-1 date: 2031-05-04

Market Authorisation Date: 03 May, 2022

Treatment: NA

Dosage: CAPSULE, TABLET;ORAL

More Information on Dosage

VOQUEZNA DUAL PAK family patents

Family Patents

3. Voquezna Triple Pak patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7977488 PHATHOM 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186411 PHATHOM Pharmaceutical composition
Aug, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 3, 2027
Generating Antibiotic Incentives Now (GAIN) May 3, 2032

Drugs and Companies using AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE ingredient

NCE-1 date: 2031-05-04

Market Authorisation Date: 03 May, 2022

Treatment: NA

Dosage: CAPSULE, TABLET, TABLET;ORAL

More Information on Dosage

VOQUEZNA TRIPLE PAK family patents

Family Patents